 CohBar, Inc. CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the Sachs Novel Coronavirus Investment Forum, being held July 7-9, 2020 with a focus on its CB5064 analogs targeting the coronavirus disease 2019 COVID-19 associated ARDS. CohBar has initiated testing of its CB5064 analogs in a preclinical model of ARDS, to assess their potential as therapeutics COVID-19 associated ARDS. 